抗凝治疗在脓毒症相关凝血病及弥散性血管内凝血中的研究进展

白云朵; 司君利

doi:10.13201/j.issn.1009-5918.2021.08.010

抗凝治疗在脓毒症相关凝血病及弥散性血管内凝血中的研究进展

白云朵,
司君利^,

- 青岛市市立医院(山东青岛, 266071)

详细信息

通讯作者: 司君利,E-mail:Junlisi@163.com

中图分类号: R459.7

收稿日期: 2021-04-14

Advance in the anticoagulant therapy for sepsis-associated coagulopathy and disseminated intravascular coagulation

BAI Yunduo,
SI Junli^,

More Information

Corresponding author: SI Junli, E-mail: Junlisi@163.com

Received Date: 14 April 2021

摘要

- 脓毒症相关凝血病 /
- 弥散性血管内凝血 /
- 抗凝治疗
Abstract: Sepsis-associated coagulopathy is defined as increased international normalized ratio and decreased platelet count. It is a highly predictive indicator of 28 day mortality. With the continuous development of this coagulation disorder, it can lead to coagulation and blood flow damage of microvessels and large vessels, the occurrence of disseminated intravascular coagulation and eventually lead to multiple organ dysfunction. So far, whether anticoagulant therapy is needed remains the focus of debate at home and abroad. Based on this, the article will review the latest treatment progress of SAC and DIC.
- sepsis-associated coagulopathy /
- disseminated intravascular coagulation /
- anticoagulant therapy

HTML全文

参考文献(42)

[1]	Rudd KE,Johnson SC,Agesa KM,et al.Global,regional,and national sepsis incidence and mortality,1990-2017:analysis for the Global Burden of Disease Study[J].Lancet,2020,395(10219):200-211.
[2]	Lyons PG,Micek ST,Hampton N,et al.Sepsis-Associated Coagulopathy Severity Predicts Hospital Mortality[J].Critical Care Medicine,2018,46(5):1.
[3]	Singer M,Deutschman CS,Seymour CW,et al.The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3)[J].Jama,2016,315(8):775-787.
[4]	Papageorgiou C,Jourdi G,Adjambri E,et al.Disseminated Intravascular Coagulation:An Update on Pathogenesis,Diagnosis,and Therapeutic Strategies[J].Clinical and Applied Thrombosis/Hemostasis,2018,24(9 Suppl):8S-28S.
[5]	Gando S,Fujishima S,Saitoh D,et al.The significance of disseminated intravascular coagulation on multiple organ dysfunction during the early stage of acute respiratory distress syndrome[J].Thrombosis Research,2020,191:15-21.
[6]	Levi M,Tom V.Coagulation and sepsis[J].Thrombosis Research,2017,149(Complete):38-44.
[7]	Conway EM.Thrombin:Coagulation's master regulator of innate immunity[J].J Thromb Haemost,2019,17(11):1785-1789.
[8]	Huebner BR,Moore EE,Moore HB,et al.Thrombin Provokes Degranulation of Platelet α-Granules Leading to the Release of Active Plasminogen Activator Inhibitor-1(PAI-1)[J].Shock,2018,50(6):671-676.
[9]	严思棋,郭涛.弥散性血管内凝血诊断与相关分子标志物[J].临床血液学杂志,2019,32(1):18-20.
[10]	Hoshino K,Kitamura T,Nakamura Y,et al.Usefulness of plasminogen activator inhibitor-1 as a predictive marker of mortality in sepsis[J].J Int Care,2017,5(1):42.
[11]	Iba T,Levy JH.Derangement of the endothelial glycocalyx in sepsis[J].J Thromb Haemost,2019,17(2):283-294.
[12]	Lsa B,Mr C,Jha D,et al.First visualization of circulating neutrophil extracellular traps using cell fluorescence during human septic shock-induced disseminated intravascular coagulation[J].Thromb Res,2019,183:153-158.
[13]	Yang X,Cheng X,Tang Y,et al.The role of type 1 interferons in coagulation induced by gram-negative bacteria-ScienceDirect[J].Blood,2020,135(14):1087-1100.
[14]	Iba T,Levy JH,Raj A,et al.Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation[J].J Clin Med,2019,8(5):728.
[15]	Vincent JL,Francois B,Zabolotskikh I,et al.Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy:The SCARLET Randomized Clinical Trial[J].JAMA,2019,321(20):1993-2002.
[16]	Tawara S,Sakai T,Matsuzaki O.Anti-inflammatory and anti-fibrinolytic effects of thrombomodulin alfa through carboxypeptidase B2 in the presence of thrombin[J].Thromb Res,2016,147:72-79.
[17]	Vincent JL,Ramesh MK,Ernest D,et al.A randomized,double-blind,placebo-controlled,Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin,ART-123,in patients with sepsis and suspected disseminated intravascular coagulation.[J].Crit Care Med,2013,41(9):2069-2079.
[18]	Hoppensteadt D,Tsuruta K,Cunanan J,et al.Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin.[J].Clin Appl Thromb Hemost,2014,20(2):129-135.
[19]	Poll T.Recombinant Human Soluble Thrombomodulin in Patients With Sepsis-Associated Coagulopathy:Another Negative Sepsis Trial?[J].JAMA,2019,321(20):1978-1980.
[20]	Levi M,Vincent JL,Tanaka K,et al.Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy[J].Critl Care Med,2020,48(8):1140-1147.
[21]	François B,Fiancette M,Helms J,et al.Efficacy and safety of human soluble thrombomodulin(ART-123) for treatment of patients in France with sepsis-associated coagulopathy:post hoc analysis of SCARLET[J].Ann Intensive Care,2021,11(1):53.
[22]	Guilamet M,Bernauer M,Micek ST,et al.Cluster analysis to define distinct clinical phenotypes among septic patients with bloodstream infections[J].Medicine (Baltimore),2019,98(16):e15276.
[23]	Seymour CW,Kennedy JN,Wang S,et al.Derivation,Validation,and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis[J].JAMA,2019,321(20):2003-2017.
[24]	Zhang Z,Zhang G,Goyal H,et al.Identification of subclasses of sepsis that showed different clinical outcomes and responses to amount of fluid resuscitation:a latent profile analysis[J].Crit Care,2018,22(1):347.
[25]	Kudo D,Goto T,Uchimido R,et al.Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin:an analysis of three multicentre observational studies[J].Crit Care,2021,25(1):114.
[26]	Umemura Y,Yamakawa K,Ogura H,et al.Efficacy and safety of anticoagulant therapy in three specific populations with sepsis:a meta-analysis of randomized controlled trials.[J].J Thromb Haem,2016,14(3):518-530.
[27]	Fan Y,Jiang M,Gong D,et al.Efficacy and safety of low-molecular-weight heparin in patients with sepsis:a meta-analysis of randomized controlled trials[J].Sci Rep,2016,6:25984.
[28]	王袁,王玲,王立民,等.肝素对脓毒症患者外周血炎症因子及凝血功能的影响[J].华北理工大学学报(医学版),2021,23(2):85-88.
[29]	王仲,魏捷,朱华栋,等.中国脓毒症早期预防与阻断急诊专家共识[J].临床急诊杂志,2020(7):517-529.
[30]	Levy JH,Sniecinski RM,Welsby I J,et al.Antithrombin:Anti-inflammatory properties and clinical applications[J].Thromb Haemost,2016 Apr;115(4):712-28.
[31]	Sungurlu S,Kuppy J,Balk RA.Role of Antithrombin Ⅲand Tissue Factor Pathway in the Pathogenesis of Sepsis[J].Crit Care Clin,2020,36(2):255-265.
[32]	Hayakawa M,Kudo D,Saito S,et al.Antithrombin Supplementation and Mortality in Sepsis-Induced Disseminated Intravascular Coagulation:A Multicenter Retrospective Observational Study[J].Shock,2016,46(6):623-631.
[33]	Kuroda H,Masuda Y.Comparison of Protective Effects of Recombinant Antithrombin Gamma and Plasma-Derived Antithrombin on Sepsis-Induced Disseminated Intravascular Coagulation and Multiple Organ Failure[J].Clin Appl Thromb Hemost,2020,26:1-8.
[34]	Yasuda N,Goto K,Ohchi Y,et al.The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation[J].J Crit Care,2016,36:29-34.
[35]	Abraham E,Reinhart K,Svoboda P,et al.Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis:a multicenter,randomized,placebo-controlled,single-blind,dose escalation study.[J].Crit Care Med,2001,29(11):2081-2089.
[36]	Abraham E,Reinhart K,Opal S,et al.Efficacy and Safety of Tifacogin(Recombinant Tissue Factor Pathway Inhibitor)in Severe Sepsis:A Randomized Controlled Trial[J].Jama,2003,290(2):238-247.
[37]	Ali MN,Kasetty G,Elven M,et al.TFPI-2 Protects Against Gram-Negative Bacterial Infection[J].Front Immunol,2018,9:2072.
[38]	Ranieri VM,Thompson BT,Barie PS,et al.Drotrecogin alfa(activated)in adults with septic shock.[J].New England Journal of Medicine,2012,366(22):2055-2064.
[39]	Wang D,Yang Y,Wang Y,et al.Embelin ameliorated sepsis-induced disseminated intravascular coagulation intensities by simultaneously suppressing inflammation and thrombosis[J].Biomedicine & Pharmacotherapy,2020,130:110528.
[40]	Hu J,Yan J,Rao G,et al.The Duality of Fgl2-Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant:Therapeutic Potential and Implications[J].International Reviews of Immunology,2014:325-339.
[41]	Zhou Y,Lei J,Xie Q,et al.Fibrinogen-like protein 2 controls sepsis catabasis by interacting with resolvin Dp5[J].Science Advances,2019,5(11):eaax0629.
[42]	Lei J,Zhou Y,Zhao H,et al.Dabigatran activates inflammation resolution by promoting fibrinogen-like protein 2 shedding and RvD5 n-3 DPA production[J].Theranostics,2021,11(9):4251-4261.